Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05087680 · ClinicalTrials.gov registry record · NA
An Acceptance Based PrEP Intervention to Engage Young Black MSM in the South
A NA study of HIV Prevention, sponsored by Rhode Island Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 66
- Enrollment target
- 1
- Study location
NCT05087680: Recruiting NA study of HIV Prevention, sponsored by Rhode Island Hospital.
NCT05087680 is a NA study of HIV Prevention that is actively recruiting participants, run by Rhode Island Hospital. The registered enrollment target is 66 participants, below the 380-participant average among 32 other HIV Prevention trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05087680, a NA study of HIV Prevention, is actively recruiting participants, sponsored by Rhode Island Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 66 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators will use a generalized framework for the adaptation of EBIs to inform the development of a brief Acceptance and Commitment Therapy (ACT)-based culturally appropriate pre-exposure prophylaxis (PrEP) intervention tailored to young Black men who have sex with men (YBMSM), named ACTPrEP.
Primary Outcome
ACTPrEP feasibility is measured by percentage of participants retained in the study.
Conditions Studied
Interventions
- BEHAVIORAL Enhanced Standard of Care
- BEHAVIORAL ACTPrEP
Study Locations (1)
Mississippi
- Univeristy of Mississippi Medical Center - Jackson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2023-09-14 |
| Est. Completion | 2025-12-01 |
| Phase | NA |
What NCT05087680 shows while recruiting
NCT05087680 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 380-participant average among 32 other HIV Prevention trials with a reported enrollment target (83% lower).
The record links to 1 condition, with HIV Prevention appearing as the primary indexed condition, and to 2 interventions - of which Enhanced Standard of Care is the first listed.
NCT05087680 reports a single indexed study location in Mississippi.
Frequently Asked Questions
What is clinical trial NCT05087680 about?
NCT05087680 is a clinical study titled "An Acceptance Based PrEP Intervention to Engage Young Black MSM in the South". Investigators will use a generalized framework for the adaptation of EBIs to inform the development of a brief Acceptance and Commitment Therapy (ACT)-based culturally appropriate pre-exposure prophylaxis (PrEP) intervention tailored to young Black men who have sex with men (YBMSM), named ACTPrEP.
What is the current status of trial NCT05087680?
This trial is currently recruiting. It is a NA study. The enrollment target is 66 participants. The study started on 2023-09-14. Estimated completion is 2025-12-01.
What conditions does trial NCT05087680 study?
This clinical trial studies the following conditions: HIV Prevention.
What interventions are being tested in trial NCT05087680?
The interventions under investigation include: Enhanced Standard of Care (BEHAVIORAL), ACTPrEP (BEHAVIORAL).
Who is sponsoring clinical trial NCT05087680?
This trial is sponsored by Rhode Island Hospital, which has 130 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05087680 being conducted?
This trial has 1 study location across Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Prevention
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05087680's enrollment target sits among peer trials
66 24th of 32 higher than 9 of 32 other HIV Prevention trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Prevention trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Using PrEP, Doing It for Ourselves
RECRUITING · NA
-
Client-Centered Care Coordination for Black Men Who Have Sex With Men
RECRUITING · NA
-
Behavioral Economic Intervention to Improve HIV Behaviors in Sexual Minority Individuals
RECRUITING · NA
-
Intervention to Enhance PrEP Persistence
RECRUITING · NA
-
WePrEP: Developing a PrEP Shared Decision-making Tool for Transgender Women
RECRUITING · NA
-
Hybrid Evaluation of a Home-based HIV Pre-exposure Prophylaxis Program
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI